New treatments for type 2 diabetes in the UK - An evolving landscape.

Anthony Barnett

doi:10.1016/j.pcd.2010.09.001

New treatments for type 2 diabetes in the UK - An evolving landscape.

Anthony Barnett

Birmingham Medical School

Research output: Contribution to journal › Article

1 Citation (Scopus)

Abstract

New classes of treatments for type 2 diabetes have been developed recently and are now available in the UK. This review aims to summarise key clinical efficacy, tolerability and safety data for these agents, including liraglutide, which has received preliminary review by the National Institute for Clinical Excellence (NICE) and was launched in the UK in 2009.

Original language	English
Pages (from-to)	1-7
Number of pages	7
Journal	Primary Care Diabetes
Volume	5
Issue number	1
DOIs	https://doi.org/10.1016/j.pcd.2010.09.001
Publication status	Published - 1 Apr 2011

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.pcd.2010.09.001

Cite this

@article{d65dc1cee98b4f69811f22b6a29d37e6,

title = "New treatments for type 2 diabetes in the UK - An evolving landscape.",

abstract = "New classes of treatments for type 2 diabetes have been developed recently and are now available in the UK. This review aims to summarise key clinical efficacy, tolerability and safety data for these agents, including liraglutide, which has received preliminary review by the National Institute for Clinical Excellence (NICE) and was launched in the UK in 2009.",

author = "Anthony Barnett",

year = "2011",

month = apr,

day = "1",

doi = "10.1016/j.pcd.2010.09.001",

language = "English",

volume = "5",

pages = "1--7",

journal = "Primary Care Diabetes",

issn = "1878-0210",

publisher = "Elsevier",

number = "1",

}

TY - JOUR

T1 - New treatments for type 2 diabetes in the UK - An evolving landscape.

AU - Barnett, Anthony

PY - 2011/4/1

Y1 - 2011/4/1

N2 - New classes of treatments for type 2 diabetes have been developed recently and are now available in the UK. This review aims to summarise key clinical efficacy, tolerability and safety data for these agents, including liraglutide, which has received preliminary review by the National Institute for Clinical Excellence (NICE) and was launched in the UK in 2009.

AB - New classes of treatments for type 2 diabetes have been developed recently and are now available in the UK. This review aims to summarise key clinical efficacy, tolerability and safety data for these agents, including liraglutide, which has received preliminary review by the National Institute for Clinical Excellence (NICE) and was launched in the UK in 2009.

U2 - 10.1016/j.pcd.2010.09.001

DO - 10.1016/j.pcd.2010.09.001

M3 - Article

C2 - 20934929

SN - 1878-0210

VL - 5

SP - 1

EP - 7

JO - Primary Care Diabetes

JF - Primary Care Diabetes

IS - 1

ER -

New treatments for type 2 diabetes in the UK - An evolving landscape.

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this